LS
MRNA icon

Livforsakringsbolaget Skandia’s Moderna MRNA Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,772
Closed -$78.5K – 553
2025
Q1 		$78.5K Hold
2,772
– – ﹤0.01% 515
2024
Q4 		$115K Hold
2,772
– – 0.01% 482
2024
Q3 		$185K Buy
2,772
+2,039
+278% +$187K 0.01% 434
2024
Q2 		$87K Hold
733
– – 0.01% 309
2024
Q1 		$78.1K Hold
733
– – 0.01% 341
2023
Q4 		$72.9K Sell
733
-3,867
-84% -$325K 0.01% 344
2023
Q3 		$475K Hold
4,600
– – 0.05% 207
2023
Q2 		$559K Sell
4,600
-400
-8% -$53.4K 0.06% 205
2023
Q1 		$768K Hold
5,000
– – 0.08% 193
2022
Q4 		$898K Hold
5,000
– – 0.1% 168
2022
Q3 		$591K Sell
5,000
-2,400
-32% -$364K 0.07% 183
2022
Q2 		$1.06M Sell
7,400
-800
-10% -$114K 0.09% 166
2022
Q1 		$1.41M Hold
8,200
– – 0.09% 164
2021
Q4 		$2.08M Sell
8,200
-1,300
-14% -$380K 0.13% 146
2021
Q3 		$3.66M Sell
9,500
-800
-8% -$295K 0.23% 102
2021
Q2 		$2.42M Buy
10,300
+3,600
+54% +$643K 0.14% 140
2021
Q1 		$877K Buy
6,700
+2,500
+60% +$362K 0.06% 239
2020
Q4 		$439K Buy
4,200
+2,100
+100% +$212K 0.04% 331
2020
Q3 		$149K Sell
2,100
-1,900
-48% -$132K 0.02% 452
2020
Q2 		$257K Buy
+4,000
New +$219K 0.03% 338

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Livforsakringsbolaget Skandia's MRNA Position: Q2 2025 in Review

Livforsakringsbolaget Skandia sold out of Moderna (MRNA) in Q2 2025, closing a stake of 2,772 shares — an estimated $78.5K sold.

Livforsakringsbolaget Skandia first reported a position in MRNA in Q2 2020 and held it in 20 quarters. The position peaked at $3.66M in Q3 2021. 675 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Livforsakringsbolaget Skandia reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Livforsakringsbolaget Skandia sold 2,772 Moderna shares in Q2 2025, an estimated $78.5K.
  • Livforsakringsbolaget Skandia first reported a position in Moderna in Q2 2020 and held it in 20 quarters.
  • Livforsakringsbolaget Skandia's Moderna position peaked at $3.66M in Q3 2021.
  • 675 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Livforsakringsbolaget Skandia's 13F filing for Q2 2025, filed 9 Jul 2025.